News Releases
All Releases
View Summary Innovative Administration of Peregrine Pharmaceuticals' Radiolabeled TNT Successfully Treats Inoperable Lung Cancer
Jun 19, 2002
PDF 11.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces U.S. Patent Granted for New Cancer Treatment
Jun 18, 2002
PDF 9.1 KB Add to Briefcase
View Summary Patent for Peregrine Pharmaceuticals' Vasopermeation Enhancement Technology Issued
Jun 17, 2002
PDF 8.8 KB Add to Briefcase
View Summary New Class of Anti-Cancer Agents Highlighted At First International Conference On Vascular Targeting
Jun 13, 2002
PDF 10.0 KB Add to Briefcase
View Summary Peregrine's Vascular Targeting Agent Platform Selectively Destroys Blood Supply to Cancer Tumors in an Animal Model
Jun 11, 2002
PDF 9.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Vascular Targeting Agent Technology At BIO 2002
Jun 10, 2002
PDF 10.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Data On Vasopermeation Enhancement Agent Technology At American Society of Clinical Oncology Annual Meeting
May 21, 2002
PDF 10.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Development of Genetically Engineered TNT Antibody Fragments Expressed in Mammalian Cells
May 14, 2002
PDF 9.8 KB Add to Briefcase
View Summary Brain Tumor Action Week Pushes Disease Into Spotlight; Advances in Biotechnology Yield Promising Brain Tumor Treatments
May 7, 2002
PDF 6.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Abstracts of Interim Results From Tumor Necrosis Therapy Treatment of Lung and Hepatic Cancers
May 7, 2002
PDF 9.8 KB Add to Briefcase
View Summary Correcting Symbol Interpretations; Greater Than Sted Less Than
May 7, 2002
PDF 5.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Sponsors Education Day During Brain Tumor Action Week; Week of May 5-11 Includes Advocacy Events and Candlelight Vigil
May 6, 2002
PDF 8.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Advances in Vascular and Tumor Targeting Technologies at American Association for Cancer Research Annual Meeting
Apr 9, 2002
PDF 10.6 KB Add to Briefcase
View Summary Avid Bioservices Announces Manufacturing Supply Agreement With Inhibitex for the Production of Therapeutic Monoclonal Antibodies
Mar 19, 2002
PDF 6.9 KB Add to Briefcase
View Summary Peregrine Announces Quarterly Conference Call
Mar 18, 2002
PDF 6.8 KB Add to Briefcase
View Summary Avid Bioservices Announces Manufacturing Supply Agreement for the Production of a Therapeutic Monoclonal Antibody Intended for Phase III Clinical Trials
Mar 13, 2002
PDF 7.2 KB Add to Briefcase
View Summary Avid Bioservices Enters Into a Manufacturing and Supply Agreement With Seradyn
Mar 6, 2002
PDF 6.6 KB Add to Briefcase
View Summary Peregrine Announces Grant of Patent for New Class of Vascular Targeting Agents
Mar 4, 2002
PDF 8.2 KB Add to Briefcase
View Summary Peregrine and OXiGENE Conclude Arcus Therapeutics LLC Joint Venture; Companies Reacquire Full Rights to Respective Vascular Targeting Technologies
Feb 28, 2002
PDF 9.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces $2.2 Million Investment From Institutional Investors
Feb 4, 2002
PDF 7.3 KB Add to Briefcase
Showing 601-620 of 628 Page: 1 ... 27 28 29 30 31 32  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail